Federal Project Grant Award Summary

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital's Research Management Division a $830,944 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 17, 2026, with a completion date of June 30, 2031. This award funds the development and application of novel value-of-information (VOI) analytical methods to optimize human immunodeficiency virus (HIV) and tuberculosis (TB) clinical trial design and priority-setting. The research team will advance methodological approaches for estimating the VOI of new clinical trials while accounting for alternative implementation priorities, eligibility criteria, and subgroup considerations. These enhanced analytical methods will be integrated into existing microsimulation models to address emerging challenges in HIV/TB clinical trial development.

The project deliverables include applied research assessing the value of clinical trials targeting underrepresented populations, emerging TB vaccine candidates, and long-acting HIV medications. The work directly supports NIH Office of AIDS Research priorities by maximizing information yield from limited trial budgets through cross-cutting HIV and comorbid TB research and health economics modeling. By providing decision makers with evidence-based frameworks for allocating constrained research resources, this project ultimately aims to improve clinical trial efficiency and health outcomes for people living with HIV and TB.